Page URL:

Gene test identifies breast cancer patients who can avoid chemotherapy

5 October 2015
Appeared in BioNews 822

A genetic test that can identify women with early-stage breast cancer who can be spared unnecessary treatment with chemotherapy has been shown to be effective in a clinical study.

By looking at several genes in the tumour, the test – called Oncotype Dx – can assess how aggressive the disease is. This information can then be used by clinicians to help decide whether hormonal-based therapy is enough to treat the tumour or if chemotherapy is needed.

Initial data from the TAILORx trial being carried out by the US National Institutes of Health, and involving over 10,000 women with early-stage breast cancer, demonstrated that women given a low recurrence score by the test may effectively use hormone therapy alone. Patients with a recurrence score of 10 or less and receiving hormone therapy alone had a less than one percent chance of their cancer returning at five years.

'These findings will give women with early-stage breast cancer greater certainty that anti-oestrogen [hormonal] therapy will decrease their risk of recurrence and increase their chance for survival whereas chemotherapy will not,' says Dr Mary Lou Smith, a breast cancer survivor who helped design the study through her role as a leader in the ECOG-ACRIN Cancer Research Advocates Committee.

The Oncotype Dx test looks at the expression of 21 genes in the tumour. This information is used to calculate a recurrence score on a scale of 0–100 that predicts how likely it is that the breast cancer will recur; the lower the score the less aggressive the tumour is.

Although the test initially came onto the market in 2004 after being tested in archived breast-cancer tissue samples, until now the test's capability to predict whether a patient would or would not benefit from chemotherapy had not been fully evaluated in a clinical trial

The patients involved in the study had early-stage breast cancer, small tumours that had no mutation in the HER2 gene, and no spread of cancer to their lymph nodes. The current guidelines in the USA recommend that these women receive chemotherapy to prevent the cancer from recurring, depending on the size or grade of the tumour.

In the trial, over 1600 women with a recurrence score of 0–10 (those at low risk of their disease returning) were randomly assigned to receive hormonal therapy without chemotherapy. At five years, 98 percent were alive, and almost 94 percent remained disease free, showing that some women can be effectively treated with hormonal-based anti-cancer drugs alone.

This means that patients who might benefit from potentially life-saving chemotherapy can be identified, while those who do not need it can be spared from unnecessary treatment and the side effects that come with chemotherapy.

'What we've shown is that if you have a low recurrence score, you do really, really well with [hormone] therapy alone,' says Professor Joseph Sparano, lead author of the study and associate chairman of oncology at Montefiore Medical Center.

'The likelihood of responding to chemotherapy would be nil. So I think we can be much more confident in making the recommendation to just use [hormone] therapy alone, especially in patients where we might have been a little skittish about recommending sparing chemotherapy.'

However, the score cut off-of 10 is only arbitrary, and it is possible that women with a higher recurrence score could also avoid chemotherapy. This theory is being tested as the trial continues to monitor patients with recurrence scores between 11 and 25, a group that represents a much higher proportion of patients.

Early Stage Breast Cancer May Not Require Chemo
Time |  28 September 2015
Gene Test Helps Some Breast-Cancer Patients Skip Chemo, Study Says
Wall Street Journal |  28 September 2015
New England Journal of Medicine publishes initial data from TAILORx breast cancer trial
Eurekalert (press release) |  28 September 2015
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
New England Journal of Medicine |  28 September 2015
TAILORx Trial Data Reinforces Oncotype DX Utility; Questions Remain on Middle Risk Group
Genomeweb |  28 September 2015
9 May 2016 - by Dr Hannah Somers 
What researchers claim as the largest-ever whole-genome sequencing study in breast cancer has revealed five previously unidentified genes which drive the development of the disease...
11 January 2016 - by Dr Lucy Freem 
A study involving more than 200,000 Nordic twins has found that cancer is 33 percent heritable...
30 November 2015 - by Dr Mary Yarwood 
More young women in the USA with cervical cancer are having fertility-sparing treatment due to earlier diagnosis...
9 November 2015 - by Ayala Ochert 
Scientists say it may be possible to track the progress of cancer – and cancer treatment – in real time from fragments of tumour DNA that are shed into the bloodstream...
26 October 2015 - by Dr Nicoletta Charolidi 
A stem-cell therapy in mice shows promise for reversing infertility in women who have received cancer treatment...
28 September 2015 - by Neil Stoker 
Researchers have identified genetic differences in breast cancers that relapse and those that do not, suggesting that the finding could be used to help doctors identify patients most at risk of their cancer returning...
1 September 2015 - by Dr Hannah Somers 
Scientists have developed a blood test that can predict several months in advance which breast cancer patients will relapse.
9 February 2015 - by Dr Molly Godfrey 
A genetic test to estimate the chance of breast cancer recurrence after surgery is set to become more widely available on the NHS....
30 September 2013 - by David O'Rourke 
A new genetic test that can estimate the risk of breast cancer in women returning after surgery has been approved for use in the NHS....
22 April 2013 - by Siobhan Chan 
Scientists have identified an eight-gene 'signature' that can predict patients' response to chemotherapy...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.